Fraunhofer ITEM and Corat Therapeutics GmbH start accelerated production of a passive vaccine against COVID-19

Press Release / July 16, 2020

Antibodies open a treatment option for patients who are already infected with SARS-CoV-2. The Braunschweig-based Division of Pharmaceutical Biotechnology of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, in collaboration with Corat Therapeutics GmbH, will begin production of a specific SARS-CoV-2 antibody that is expected to enter clinical trials as early as the beginning of 2021.